Smooth muscle differentiation identifies two classes of poorly differentiated pleomorphic sarcomas with distinct outcome

Modern Pathology

Volumn 27, Issue 6, 2014, Pages 840-850

  Pérot, Gaëlle ^a,b   Mendiboure, Jean ^a   Brouste, Véronique ^a   Velasco, Valérie ^a   Terrier, Philippe ^c   Bonvalot, Sylvie ^c   Guillou, Louis ^d   Ranchère Vince, Dominique ^e   Aurias, Alain ^a,b   Coindre, Jean Michel ^a,b   Chibon, Frédéric ^a,b  

^a INSTITUT BERGONIÉ   (France)

^b INSERM   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

^e CENTRE LÉON BÉRARD   (France)

Author keywords

immunohistochemistry; leiomyosarcoma; prognosis; smooth muscle differentiation; undifferentiated pleomorphic sarcoma

Indexed keywords

CALDESMON; CALPONIN; SMOOTH MUSCLE ACTIN; TRANSGELIN; TUMOR MARKER;

ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CHROMOSOME ARM; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; METASTASIS; PHENOTYPE; PLEOMORPHIC SARCOMA; PRIORITY JOURNAL; SARCOMA; SCORING SYSTEM; SMOOTH MUSCLE; TISSUE DIFFERENTIATION; CELL DIFFERENTIATION; CLASSIFICATION; MORTALITY; PATHOLOGY; PROGNOSIS; SOFT TISSUE TUMOR;

CELL DIFFERENTIATION; HUMANS; IMMUNOHISTOCHEMISTRY; MUSCLE, SMOOTH; PROGNOSIS; SARCOMA; SOFT TISSUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84901819656     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.205     Document Type: Article

References (27)

1. Fletcher CDM, Gronchi A, Singer S, et al. Tumours of soft tissue: introduction, In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (eds). World Health Organisation Classification of Tumours of Soft Tissue and Bone. IARC Press: Lyon, France; 2013, pp 13-18.
2. Coindre JM, Pedeutour F, Aurias A. Well-differentiated and dedifferentiated liposarcomas. Virchows Arch 2010;456:167-179.
3. Guillou L, Aurias A. Soft tissue sarcomas with complex genomic profiles. Virchows Arch 2010;456:201-217.
4. Chibon F, Mariani O, Derré J, et al. A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas. Cancer Genet Cytogenet 2002;139:24-29. (Pubitemid 36120402)
5. Chibon F, Mariani O, Mairal A, et al. The use of clustering software for the classification of comparative genomic hybridization data. An analysis of 109 malignant fibrous histiocytomas. Cancer Genet Cyto-genet 2003;141:75-78. (Pubitemid 36165199)
6. Lazar A, Evans HL, Shipley J. Leiomyosarcoma, In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (eds). World Health Organisation Classification of Tumours of Soft Tissue and Bone. IARC Press: Lyon, France; 2013, pp 111-115.
7. Fletcher CDM, Chibon F, Mertens F. Undifferentiated/unclassified sarcoma, In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (eds). World Health Organisation Classification of Tumours of Soft Tissue and Bone. IARC Press: Lyon, France; 2013, pp 236-238.
8. Fletcher CD, Gustafson P, Rydholm A, et al. Clinico-pathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassifica-tion. J Clin Oncol 2001;19:3045-3050. (Pubitemid 32565442)
9. Deyrup AT, Haydon RC, Huo D, et al. Myoid differentiation and prognosis in adult pleomorphic sarcomas of the extremity: an analysis of 92 cases. Cancer 2003;98:805-813. (Pubitemid 36959278)
10. Mills AM, Beck AH, Montgomery KD, et al. Expression of subtype-specific group 1 leiomyosarcoma markers in a wide variety of sarcomas by gene expression analysis and immunohistochemistry. Am J Surg Pathol 2011;35:583-589.
11. Pérot G, Derré J, Coindre JM, et al. Strong smooth muscle differentiation is dependent on myocardin gene amplification in most human retroperitoneal leiomyosarcomas. Cancer Res 2009;69:2269-2278.
12. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
13. Chibon F, Lagarde P, Salas S, et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med 2010;16: 781-787.
14. Robin YM, Penel N, Pérot G, et al. Transgelin is a novel marker of smooth muscle differentiation that improves diagnostic accuracy of leiomyosarcomas: a comparative immunohistochemical reappraisal of myogenic markers in 900 soft tissue tumors. Mod Pathol 2013;26: 502-510.
15. Ono H, Yoshikawa H, Ueda T, et al. Expression of smooth muscle calponin in synovial sarcoma. Sarcoma 1999;3:107-113. (Pubitemid 29484563)
16. Fisher C, Montgomery E, Healy V. Calponin and h-caldesmon expression in synovial sarcoma; the use of calponin in diagnosis. Histopathology 2003;42:588-593. (Pubitemid 36688153)
17. Italiano A, Lagarde P, Brulard C, et al. Genetic profiling identifies two classes of soft-tissue leiomyosarcomas with distinct clinical characteristics. Clin Cancer Res 2013;19:1190-1196.
18. Pipes GC, Creemers EE, Olson EN. The myocardin family of transcriptional coactivators: versatile regulators of cell growth, migration, and myogenesis. Genes Dev 2006;20:1545-1556. (Pubitemid 43901093)
19. Mayanagi T, Sobue K. Diversification of caldesmon-linked actin cytoskeleton in cell motility. Cell Adh Migr 2011;5:150-159.
20. Horiuchi A, Nikaido T, Taniguchi S, et al. Possible role of calponin h1 as a tumor suppressor in human uterine leiomyosarcoma. J Natl Cancer Inst 1999;91: 790-796. (Pubitemid 29239059)
21. Lee EK, Han GY, Park HW, et al. Transgelin promotes migration and invasion of cancer stem cells. J Proteome Res 2010;9:5108-5117.
22. Grunewald TG, Pasedag SM, Butt E. Cell adhesion and transcriptional activity-defining the role of the novel protooncogene LPP. Transl Oncol 2009;2:107-116.
23. Majesky MW. Organizing motility: LIM domains, LPP, and smooth muscle migration. Circ Res 2006;98: 306-308.
24. Petit MM, Lindskog H, Larsson E, et al. Smooth muscle expression of lipoma preferred partner is mediated by an alternative intronic promoter that is regulated by serum response factor/myocardin. Circ Res 2008;103: 61-69.
25. Milyavsky M, Shats I, Cholostoy A, et al. Inactivation of myocardin and p16 during malignant transformation contributes to a differentiation defect. Cancer Cell 2007;11:133-146. (Pubitemid 46209846)
26. Madonna R, Wu D, Wassler M, et al. Myocardin-A enhances expression of promyogenic genes without depressing telomerase activity in adipose tissue-derived mesenchymal stem cells. Int J Cardiol 2012;159.
27. Medjkane S, Perez-Sanchez C, Gaggioli C, et al. Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis. Nat Cell Biol 2009;11:257-268.